Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SPF Fraud Cases Hard To Shake, Could Shine Light On FDA Protocol Problems

Executive Summary

As SPF defendants’ dismissal motions continue to be shot down in federal courts, it increasingly seems that their SPF claims and the radically different test results alleged by plaintiffs will have to be subjected to rigorous analysis and expert opinion, undertakings that could shine light on inherent problems with FDA’s testing protocol rather than overt moves by companies to inflate the protective capacity of their products.


Related Content

What’s In A Name? Babyganics Settles False Advertising Allegations To Tune Of $2.2M
Pollution Protection, Blue Light Defense Among Cosmetic Tests In High Demand
SPF Claims No More Reliable In 2018 Than Previous Years – Consumer Reports
FDA Tightlipped On Status Of ‘SPF Determination’ Study, But Issue Is A Concern
Sunscreen Firms’ SPF Court Battles Go On, While Consumer Reports Prepares 2018 Review
Coppertone Sunscreens SPF At Half Of Label Level, Class Actions Allege
Sun Protection Fraud? Class Actions Dispute Brands' Claimed SPFs





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts